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Edited by Laszlo NagyAbstract Inhibition of the lipid phosphatase SH2-domain con-
taining inositol phosphatase 2 (SHIP2) in L6-C10 muscle cells,
in 3T3-L1 adipocytes and in the liver of db/db mice has been
shown to ameliorate insulin signal transduction and established
SHIP2 as a negative regulator of insulin action. Here we show
that SHIP2 inhibition in INS1E insulinoma cells increased
Akt, glycogen synthase kinase 3 and extracellular signal-regu-
lated kinases 1 and 2 phosphorylation. SHIP2 inhibition did
not prevent palmitate-induced apoptosis, but increased cell pro-
liferation. Our data raise the interesting possibility that SHIP2
inhibition exerts proliferative eﬀects in b-cells and further sup-
port the attractiveness of a speciﬁc inhibition of SHIP2 for the
treatment of type 2 diabetes.
 2007 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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Type 2 diabetes is characterized by insulin resistance of
insulin target tissues and impaired insulin secretion from pan-
creatic b-cells. During progression of type 2 diabetes the ini-
tial expansion of b-cell mass partially compensates for the
peripheral insulin resistance. After prolonged impaired glu-
cose tolerance the progressive decline of pancreatic b-cell
mass together with b-cell dysfunction contributes to the path-
ogenesis of type 2 diabetes [1]. The b-cell mass is regulated by
an interplay of apoptosis and proliferation. Important b-cell
survival and growth factors are insulin, insulin-like growth
factor-I, hepatocyte growth factor, glucagon-like peptide 1
(GLP-1) and GIP. Several ﬁndings suggest that the phospha-Abbreviations: bGal, beta-galactosidase; ERK1/2, extracellular signal-
regulated kinases 1 and 2; GLP-1, glucagon-like peptide 1; GSK3,
glycogen synthase kinase 3; PI3K, phosphatidylinositol 3-kinase; PKB
(Akt), protein kinase B; PtdIns(3,4,5)P3, phosphatidylinositol 3,4,5-
trisphosphate; SHIP2, SH2-domain containing inositol phosphatase 2
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pathway is important for b-cell growth and survival. Overex-
pression of a constitutively active form of Akt in vivo en-
hances cell survival and cell proliferation and thereby
increases b-cell mass [2,3]. Akt phosphorylates and thereby
inactivates a number of pro-apoptotic proteins like glycogen
synthase kinase 3 alpha/beta (GSK3a/b), BAD, Caspase-9
or FoxO1 [4]. Therefore, it is conceivable that factors that in-
crease endogenous Akt phosphorylation and activation en-
hance the proliferation of b-cells and/or inhibit b-cell
apoptosis [5].
The second messenger phosphatidylinositol 3,4,5-trisphos-
phate (PtdIns(3,4,5)P3), generated by PI3K, is a key compo-
nent of insulin signal transduction [6]. SH2-domain
containing inositol phosphatase 2 (SHIP2) is expressed in
insulin target tissues and in the pancreas [7] and dephospho-
rylates PtdIns(3,4,5)P3 at position 5 [8,9]. A 16 bp deletion
in the 3 0-untranslated region of the human SHIP2 gene which
leads to overexpression of SHIP2 contributes to the genetic
susceptibility to type 2 diabetes in humans [10]. In agreement
with these data, liver-speciﬁc overexpression of SHIP2 in db/+
mice decreased insulin-induced Akt phosphorylation and
causes hepatic insulin resistance [11]. On the other hand, the
liver-speciﬁc overexpression of a phosphatase defective SHIP2
mutant that acts in a dominant negative manner (dnSHIP2) in
diabetic KKAy-mice as well as in diabetic db/db-mice showed
a marked reduction of blood glucose [11,12]. At the cellular
level, inhibition of SHIP2 via overexpression of dnSHIP2
has been shown to increase phosphorylation of Akt in diﬀer-
entiated L6 myotubes, 3T3-L1 adipocytes and in C3A hepa-
toma cells [12–14]. In L6 myotubes and 3T3-L1 adipocytes
the increased phosphorylation of Akt leads to an enhanced
glycogen synthase activity with an enhanced glycogen synthe-
sis rate [13,14].
Although it has been shown that insulin signalling plays an
important role for b-cell function [15], the eﬀects of SHIP2
inhibition in b-cells are completely unknown. It is intriguing
that SHIP2 inhibition could enhance insulin signal transduc-
tion in b-cells and could thereby protect the cells from apop-
tosis or induce proliferation, both of which would be
beneﬁcial for type 2 diabetics. To gain insight into the eﬀects
of SHIP2 inhibition in b-cells we used adenovirus-mediated
gene transfer for overexpression of a dominant negative
SHIP2 mutant in the insulin-producing cell line INS1E and
analysed the impact on insulin signal transduction, apoptosis
and proliferation.blished by Elsevier B.V. All rights reserved.
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2.1. Reagents
The following antibodies were used: polyclonal anti-phospho
(Ser473)-Akt, anti-phospho (Ser9/21)-GSK3a/b, anti-phospho (Thr202/
Tyr204)-extracellular signal-regulated kinases 1 and 2 (ERK1/2), anti-
Akt, anti-GSK3b and anti-ERK1/2 (Cell Signaling Technology, Bever-
ley, MA), anti-cyclin A and anti-b-actin (Santa Cruz Biotechnology,
Santa Cruz, CA). All other reagents were of analytical grade and pur-
chased from Sigma–Aldrich (Gillingham, UK) or Roche Applied Sci-
ence (Mannheim, Germany).
2.2. Cell culture and infection with adenoviruses
The construction of recombinant adenoviruses expressing b-galacto-
sidase and dominant negative SHIP2 has been described previously
[12]. INS1E insulinoma cells [16,17] were maintained in RPMI 1640
containing 11 mM glucose and 2 mM glutamine (Invitrogen, Carlsbad,
CA) supplemented with 50 lM b-mercaptoethanol, 10 mM HEPES,
1 mM sodium pyruvate and 5% fetal bovine serum (FBS) at 37 C in
a humidiﬁed atmosphere with 5% CO2. Cells were infected at a multi-
plicity of infection (MOI) of 25 infectious units (IU)/cell. This results in
>90% infection of INS1E cells as determined by adenoviral eGFP
expression (data not shown). The cells were serum starved 24 h post-
infection for 2 h and incubated with or without 100 nM insulin for
10 min. Afterwards, the cells were washed with 1 · PBS and lysed in
lysis buﬀer (50 mM Tris–HCl pH 7.5, 100 mM NaCl, 50 mM NaF,
10% glycerol, 1% Triton X-100, with freshly added 1 mM DTT,
30 mM p-nitrophenyl phosphate (PNPP), 10 mM sodium orthovana-
date, Complete Mini Protease Inhibitor Cocktail tablets (1 tbl per
10 ml) (Roche Applied Science)). Lysates were frozen in liquid nitro-
gen and stored at 80 C.
2.3. Expression analysis
Total RNA was extracted from INS1E cells using the RNeasy Mini
Kit (Qiagen, Hilden, Germany) according to the manufacturers
instructions and 100 ng RNA was transcribed into cDNA. Cyclin A
mRNA levels were quantiﬁed using a TaqMan real-time quantitative
PCR (qRT-PCR) chemistry and detection system (Applied Biosystems,
Foster City, CA). All samples were run in triplicate. Relative mRNA
levels were calculated from a standard curve and normalized to the
amount of 18sRNA in the sample.
2.4. Immunoblotting
Protein concentrations of INS1E cell lysates were determined by the
Bradford method. The proteins (25 lg/lane) were electrophoretically
separated on 4–15% Criterion Precast Gels (BioRad, Hercules, CA)
and Western blots were performed and analysed as previously de-
scribed [12,18].
2.5. Determination of caspase-activity
Cells were infected with adenoviruses encoding bGal or dnSHIP2 as
described. After 24 h the medium was changed to RPMI without FCS
and the cells were incubated with or without 0.5 mM palmitate in the
absence or presence of 100 nM insulin for 22 h. Caspase activity was
assessed using the homogenous caspase assay (Roche Diagnostics,
Mannheim, Germany) that detects the activity of caspases 2, 3, 6, 7,
8, 9, and 10 with diﬀerent sensitivity.
2.6. Crystal violet staining
The cell number was determined by crystal violet staining. After ﬁx-
ation of the cells with 4% formaldehyde in 1 · PBS, the cells were incu-
bated with crystal violet solution (0.125% crystal violet, 5% ethanol,
2% PBS) for 1 h. Then the plates were washed three times with
1 · PBS and dried for 2 h. After incubation with 5% ethanol +1%
SDS for 1 h the absorbance was measured at 570 nm.
2.7. Proliferation assay
Proliferation was assessed by [14C] thymidine incorporation into
INS1E cells in the absence or presence of insulin. For this, the cells
were seeded in Cytostar-T 96-well scintillating microplates (Amer-
sham Biosciences, Buckinghamshire, UK) and infected as described
above. After 24 h the medium was changed to RPMI without FCS
and the cells were incubated with 2ll [14C] thymidine (1.85 MBq/ml)per well for 22 h with diﬀerent insulin concentrations. Incorporation
of radioactive thymidine was measured with a TopCount NXT (Per-
kin–Elmer Life Sciences, Wellesley, MA).2.8. Statistical analysis
Results are given as means ± S.E.M. For comparisons the unpaired
Students t-test was used. Parameters with values P < 0.05 were consid-
ered to diﬀer signiﬁcantly.3. Results
3.1. Overexpression of a dominant negative SHIP2 mutant
improves phosphorylation of Akt, GSK3 and ERK1/2 in
INS1E insulinoma cells
Consistent with SHIP2 expression in the human pancreas
[7], expression of endogenous SHIP2 was also detected in
INS1E cells (Fig. 1A). A phosphatase defective SHIP2
mutant that acts in a dominant negative fashion has been de-
scribed previously [13]. A similar human SHIP2 mutant
(dnSHIP2) was constructed and expressed via adenovirus
mediated gene transfer in INS1E cells. As a control, an ade-
novirus encoding beta-galactosidase (Ad5-bGal) was used in
all experiments. INS1E cells were infected and the basal
and insulin-induced Akt phosphorylation was analysed by
Western blot. Overexpression of dnSHIP2 was 5- to 6-fold
over endogenous SHIP2 in all experiments (Fig. 1A). The
overexpression of dnSHIP2 resulted in a signiﬁcant increase
of Akt and GSK3 phosphorylation in the absence or presence
of 100 nM insulin (Fig. 1A–D). Furthermore, overexpression
of dnSHIP2 signiﬁcantly increased the phosphorylation of
both ERK1 and ERK2 in the absence of insulin, but not in
the presence of insulin (Fig. 1E/F). Therefore, functional
SHIP2 inhibition increased the basal and insulin-induced
phosphorylation of Akt and GSK3 but only increased basal
ERK1/2 phosphorylation.3.2. Overexpression of dnSHIP2 does not protect INS1E cells
against palmitate-induced apoptosis
To assess the impact of SHIP2 inhibition on apoptosis,
INS1E cells were infected with Ad5-bGal or Ad5-dnSHIP2
as described above and incubated for 22 h with 0.5 mM palm-
itate in the absence or presence of 100 nM insulin. The cells
were then either lysed and the activity of the caspases 2, 3, 6,
7, 8, 9, and 10 was measured or ﬁxed for the determination
of the number of living cells by crystal violet staining.
SHIP2 inhibition signiﬁcantly increased the cell number inde-
pendent of treatment with palmitate or insulin (Fig. 2A). Palm-
itate incubation decreased the cell number in both dnSHIP2-
and bGal-expressing conditions to a similar extend, approxi-
mately by 30% (Fig. 2A). Therefore, dnSHIP2 expression could
not rescue the cells from palmitate-induced apoptosis.
The incubation of INS1E cells with 0.5 mM palmitate re-
sulted in a signiﬁcant increase of caspase activity (Fig. 2B).
However, dnSHIP2 overexpression was not able to signiﬁ-
cantly reduce the caspase activity in control cells and insulin-
stimulated cells (Fig. 2B).
As no diﬀerence in either caspase activity (Fig. 2B) or the
percentage of surviving cells (Fig. 2A) between the dnSHIP2
and bGal-expressing cells was observed, the data indicate that
SHIP2 inhibition may impact on cell proliferation rather than
anti-apoptosis.
Fig. 1. SHIP2 inhibition increases basal and insulin-induced phosphorylation of Akt and GSK3 and basal phosphorylation of ERK1/2. INS1E cells
were infected with adenoviruses encoding bGal or dnSHIP2. Cells were incubated with or without 100 nM insulin for 10 min. (A, C, and E) Cell lysates
were subjected to immunoblot analysis with anti-SHIP2, anti-Akt, anti-phospho (Ser473)-speciﬁc Akt, anti-phospho (Ser9/21)-speciﬁc GSK3a/b
antibodies, anti-ERK1/2 antibody or anti-phospho-(Thr202/Tyr204)-speciﬁc ERK1/2 antibody. (B, D, and F) Densitometric analysis of (B) Akt
phosphorylation, (D) GSK3 phosphorylation and (F) ERK1/2 phosphorylation of three independent experiments. Values represent means ± S.E.M.
of three independent experiments. *P < 0.05 vs. bGal-expressing controls without insulin, #P < 0.05 vs. bGal-expressing controls with insulin.
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To test the hypothesis that SHIP2 inhibition aﬀects cell prolifer-
ation of INS1E cells we infected the cells with Ad5-bGal or Ad5-
dnSHIP2, analysed the mRNA and protein level of cyclin A and
measured DNA synthesis by [14C] thymidine incorporation.
Cyclin A accumulates during the S-phase of the cell cycle
and is essential for DNA synthesis [19]. Overexpression of
dnSHIP2 led to a signiﬁcant increase in mRNA and protein
levels of cyclin A by 129% and 132%, respectively (Fig. 3A
and B). In agreement with this, a signiﬁcant increase of [14C]
thymidine incorporation was observed in dnSHIP2-over-
expressing cells in the absence of insulin and over a range of
insulin concentrations up to 10 lM, which shows increased
DNA-synthesis during S-phase (Fig. 3C).4. Discussion
Despite many studies illustrating the relevance of the insulin/
PI3K/Akt signalling pathway for b-cell growth and survival,little is known about the negative regulation of this pathway
in b-cells. The phosphatidylinositol D3-phosphatase PTEN,
which acts as a negative regulator of the PI3K pathway, inhib-
its the compensatory growth of b-cells in IRS2 / mice [20].
Here we identiﬁed the phosphatidylinositol D5-phosphatase
SHIP2 as another negative regulator of the PI3K signal trans-
duction pathway in INS1E cells. We observed enhanced Akt
phosphorylation in INS1E cells following SHIP2 inhibition
with a similar magnitude as compared to other cell types, like
3T3-L1 adipocytes, L6 myotubes or C3A hepatoma cells [12–
14]. To study the eﬀect of SHIP2 inhibition downstream of Akt
activation we measured apoptosis and proliferation rates of
INS1E cells.
We have demonstrated that SHIP2 inhibition increases [14C]
thymidine incorporation (Fig. 3C) and cell number (Fig. 2A)
of INS1E cells, which was accompanied by upregulation of
cyclin A (Fig. 3A/B). A-type cyclins accumulate during the
S-phase of the cell cycle and are essential for DNA synthesis
[19] which is in agreement with the observed increase in the
DNA synthesis rate of dnSHIP2-expressing INS1E cells. A
Fig. 2. SHIP2 inhibition does not protect INS1E cells from palmitate-
induced apoptosis. INS1E cells expressing bGal or dnSHIP2 were
incubated with or without 0.5 mM palmitate in the absence or presence
of insulin for 22 h. (A) Cell number as determined by crystal violet
staining. Values represent means ± S.E.M. *P < 0.05 decrease in cell
number after palmitate treatment compared to baseline bGal control.
(B) Homogenous caspase assay. The graph shows the caspase activity
relative to the cell number. Values represent means ± S.E.M. *P < 0.05
vs. baseline bGal control.
Fig. 3. SHIP2 inhibition increases cyclin A mRNA and protein levels
and induces proliferation of INS1E cells. INS1E cells were infected
with adenoviruses encoding bGal or dnSHIP2. After 24 h the medium
was exchanged for RPMI without serum and the cells were further
incubated for 22 h until lysis. (A) Cyclin A mRNA relative to 18s RNA
as determined by TaqMan real-time quantitative PCR. (B) Cyclin A
protein levels relative to actin protein levels as determined by
immunoblot analysis with anti-cyclin A and anti-actin antibodies.
Values represent means ± S.E.M. of three independent experiments
(n = 9). *P < 0.05 vs. bGal-expressing controls. (C) [14C] thymidine
incorporation. At 24 h post-infection the medium was changed to
RPMI without serum and the cells were incubated with [14C] thymidine
for 22 h with diﬀerent insulin concentrations (0 to 10 lM). The
incorporation of [14C] thymidine is expressed as percent of baseline
bGal control. Values represent means ± S.E.M. of three independent
experiments. *P < 0.05 vs. the respective insulin concentration in bGal-
expressing cells.
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dermal C141 cells. In these cells treatment with the protein-
tyrosine phosphatase inhibitor, sodium vanadate, dose-depen-
dently increased the phosphorylation of Akt and GSK3, en-
hanced the expression of cyclin A and increased the number
of cells in S-phase [21], which is consistent with our observa-
tions.
In agreement, strong activation of Akt by overexpression of
constitutively active Akt1 increased b-cell mass in mice in part
by increased proliferation [2,3,22]. But more importantly, pan-
creatic b-cell speciﬁc deletion of PTEN in mice which causes a
moderate increase in Akt phosphorylation also increased b-cell
proliferation [23].
The observed increase in basal thymidine incorporation is
most probably caused by multiple signalling pathways includ-
ing the PI3K/Akt pathway and the Ras/Raf/MEK/ERK-path-
way. However, the contribution of the Ras/Raf/MEK/ERK-
pathway to the increased insulin-stimulated thymidine incor-
poration remains unclear, because we did not observe an in-
crease in insulin-stimulated ERK1/2 phosphorylation after
dnSHIP2 overexpression.
In our study, we could not detect an attenuation of palmi-
tate-induced apoptosis after inhibition of SHIP2. Most reports
that provide evidence for an anti-apoptotic role of Akt in INS1
cells overexpressed a constitutively active Akt1 [24,25]. How-
ever, SHIP2 inhibition with dnSHIP2 does only cause transient
1.5- to 2-fold activation of endogenous Akt, which is not com-
parable with eﬀects caused by overexpression of a constitu-
tively active Akt that causes 10- to 100-fold activation of thepathway. Furthermore, the relative contribution of the Akt
isoforms is unknown. In 3T3-L1 cells it is established that
SHIP2 inhibition improves the phosphorylation of Akt2 rather
than Akt1 [26]. In b-cells, all three isoforms of Akt are ex-
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isoform in INS1E cells is unknown and was beyond the scope
of this study.
Although, we observed an increased phosphorylation of
GSK3 we could not detect inhibition of apoptosis an event
that is associated with GSK3 inhibition [28]. A recent study
shows that small molecule inhibitors of GSK3 can partially
rescue INS1E cells from glucolipotoxicity [28]. In this study,
a signiﬁcant anti-apoptotic eﬀect in INS1E cells (reduction of
DNA-fragmentation of 15–20%) was achieved with two struc-
turally diﬀerent GSK3 inhibitors (1-azakenpaullone and
CHIR99021) starting at concentrations of 5 lM. However, a
signiﬁcant increase in proliferation (BrdU incorporation) of
INS1E cells was already achieved at 15-fold lower concentra-
tions (0.3 lM) of both compounds. The maximum eﬀect in
the proliferation assay was reached with both compounds at
2.5 lM. This strongly suggests that full GSK3 inhibition is
needed to inhibit apoptosis, but partial GSK3 inhibition is suf-
ﬁcient to increase proliferation. We believe that the modest in-
crease in GSK3 phosphorylation in our study leads to a
moderate inhibition of GSK3, and therefore an anti-apoptotic
eﬀect can not be expected.
Taken together, we show here for the ﬁrst time that inhibi-
tion of SHIP2 improves insulin signal transduction in INS1E
insulinoma cells and thereby induces cell proliferation. Our
data raise the interesting possibility that SHIP2 inhibition ex-
erts important proliferative eﬀects in b-cells. Therefore, these
data further support the attractiveness of a speciﬁc inhibition
of SHIP2 for the prevention and/or treatment of type 2 diabe-
tes.
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